The 'fat jab' semaglutide: what the clinical evidence shows

Where the 'fat jab' label came from, and what the STEP 1 trial actually measured

The nickname has spread faster than the facts, so it's worth starting with what researchers actually observed. The STEP 1 trial enrolled 1,961 adults with obesity (BMI 30 or above) or overweight with at least one weight-related condition, none with type 2 diabetes, and randomised them to either 2.4mg semaglutide weekly or placebo alongside structured lifestyle support. After 68 weeks, those on semaglutide lost an average of around 15% of their starting body weight compared with roughly 2.4% in the placebo group. That's a meaningful clinical difference, which is why the results drew wide attention and, eventually, wide tabloid coverage.

What the headlines compressed was the context. Participants also followed a reduced-calorie diet and increased their physical activity as part of the trial protocol. The medicine works by activating GLP-1 receptors in the brain and gut (signalling satiety, slowing stomach emptying and reducing the drive to eat) but it does so most effectively when those lifestyle changes are in place alongside it. Describing that as a 'jab that melts fat' misrepresents the mechanism. The fuller picture is one of a clinically tested medicine that, for people who are eligible, shifts the biology enough to make meaningful, sustained weight reduction achievable. You can read more about how semaglutide produces fat loss in the body.

The medicine is licensed in the UK under the brand name Wegovy, and details of what the Wegovy jab involves are covered on our Wegovy page.

What semaglutide is (and is not) licensed for in the UK

This distinction matters because the same molecule, semaglutide, is sold under two different brand names in the UK for two different purposes, and conflating them is one of the most common sources of confusion online. Ozempic (0.5mg, 1mg, 2mg) is licensed for type 2 diabetes. Wegovy (up to 2.4mg, now up to 7.2mg) is licensed for weight management. They are not interchangeable, and the MHRA is clear that GLP-1 medicines are not assessed for quick or cosmetic weight loss, the clinical indication is chronic weight management in adults meeting specific BMI thresholds, alongside diet and activity changes.

On 14 April 2026, the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, designed for adults with a BMI of 30 or above. Trials at this higher dose reported average weight loss of around 20.7% over 72 weeks, bringing results closer to those seen with tirzepatide at its highest licensed dose. If you're weighing up the options, our page on fat jabs and Wegovy compares the landscape more broadly.

Rybelsus (also oral semaglutide) is a different product licensed for type 2 diabetes, not weight management. It should not be confused with Wegovy tablets, which were approved for weight loss by the MHRA in June 2026 and represent a genuinely separate, newer formulation.

Who the evidence supports, eligibility in plain terms

Many people reading about semaglutide right now are doing so because they've struggled with weight for years, tried multiple approaches, and are wondering whether this is finally something that might work for them. That's a completely understandable place to be, and the clinical evidence does support meaningful benefit for people within the licensed population.

The licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition, things like high blood pressure, raised cholesterol, obstructive sleep apnoea or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under NICE's appraisal of semaglutide (TA875), reflecting evidence that health risks associated with excess weight appear at lower BMIs in those groups. A BMI figure alone, though, doesn't settle the question. A prescriber also considers your full medical history, current medicines, and any contraindications before deciding whether treatment is appropriate.

Treatment is not recommended during pregnancy, while breastfeeding, or when trying to conceive, and it is not licensed for anyone under 18. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or with a history of pancreatitis, require careful prescriber discussion before any GLP-1 treatment.

Our weight-loss treatment overview sets out how different medicines compare for different starting points.

Side effects, safety signals and what to watch for

The side-effect profile of semaglutide is well-characterised after thousands of patient-years of trial data and real-world use. Gastrointestinal effects dominate: nausea, loose stools, constipation, indigestion and burping are the most common, particularly in the first few weeks of treatment or after a dose increase. For most people they settle as the body adjusts. Fatigue, headache and injection-site reactions are also reported, typically mild.

One signal worth knowing: in January 2026 the MHRA published a Drug Safety Update for GLP-1 medicines highlighting acute pancreatitis as an infrequent but potentially serious risk. Severe, persistent abdominal pain (especially pain that spreads to the back, with or without vomiting) warrants urgent medical attention. This isn't a reason to avoid treatment if you're clinically suitable, but it is a reason to know the symptom and act on it promptly. Suspected side effects from any medicine can be reported at the MHRA's Yellow Card scheme.

Questions about side effects come up in almost every consultation our prescribers run, so if you're uncertain how a specific symptom relates to treatment, that's exactly the kind of thing a clinical review is for. Our frequently asked questions cover some of the most common ones, and our page on semaglutide colloquially called the skinny jab addresses the broader safety conversation in more detail.

For anyone considering taking this further, the most useful next step is a proper clinical assessment rather than more reading. Start your free consultation with our prescribing team to find out whether semaglutide is appropriate for you.